RxDoctor Payments Data

Henry Duong

Optometrist · Arcadia, CANPI 1831508977

Payments from drug & device makers

$380in general payments, 2019–2025

Across 9 payments — averaging $42.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$144
  • Glaukos Corporation$106
  • Aerie Pharmaceuticals, Inc.$41
  • Oyster Point Pharma, Inc.$27
  • Rxsight Inc$21
  • Biotissue Holdings Inc.$20
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$380 in reported general payments places this provider in the 40th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$83,374
Medicare patients
308
Services billed
747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine20$24,835
Latanoprost758$10,151
Alphagan PBrimonidine Tartrate34$8,569
Cyclosporine14$7,564
Azelastine Hcl318$6,190
LumiganBimatoprost17$6,049
Brimonidine Tartrate86$3,833
Prednisolone Acetate33$1,627
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat142$1,565
Timolol Maleate105$1,236
Dorzolamide Hcl55$985
Ketorolac Tromethamine13$217
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$198
Ciprofloxacin Hcl11$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Lumigan$144$39,45271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 6,778 optometrist providers in California.

Other optometrist in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →